XL019
- Generic Name
- XL019
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- 4L1AM42NVA
- Background
XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. An IND for XL019 was filed by Exelixis in May 2007.
- Indication
For the treatment of various forms of cancer.
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 1 Study of XL019 in Adults With Polycythemia Vera
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2015-08-21
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 3
- Registration Number
- NCT00595829
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸UCSF - Division of Hematology/Oncology, San Francisco, California, United States
🇺🇸UCLA School of Medicine, Center for Health Sciences, Los Angeles, California, United States
A Safety Study of XL019 in Adults With Myelofibrosis
Phase 1
Terminated
- Conditions
- First Posted Date
- 2007-08-29
- Last Posted Date
- 2011-04-05
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 100
- Registration Number
- NCT00522574
- Locations
- 🇺🇸
UCSF - Division of Hematology/Oncology, San Francisco, California, United States
🇺🇸Mt. Sinai School of Medicine, New York, New York, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath